Biogen acquires sole rights to MS drug from Elan for $3.25B

02/7/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec agreed to pay Elan $3.25 billion plus future royalties to acquire all rights to multiple sclerosis drug Tysabri, or natalizumab. Tysabri was jointly developed by Biogen and Elan. The deal will strengthen Biogen's presence in the multiple sclerosis drug market as it awaits the FDA's decision on another MS drug, Tecfidera, or dimethyl fumarate.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA